A comparative study of AutoDock and PMF scoring performances, and SAR of 2-substituted pyrazolotriazolopyrimidines and 4-substituted pyrazolopyrimidines as potent xanthine oxidase inhibitors-Reference-Cited by-同舟云学术

A comparative study of AutoDock and PMF scoring performances, and SAR of 2-substituted pyrazolotriazolopyrimidines and 4-substituted pyrazolopyrimidines as potent xanthine oxidase inhibitors

Published:2009-12-29 Issue:1 Volume:24 Page:57-75
ISSN:0920-654X
Container-title:Journal of Computer-Aided Molecular Design
language:en
Short-container-title:J Comput Aided Mol Des

Author:

Ali Hamed I.,Fujita Takayuki,Akaho Eiichi,Nagamatsu Tomohisa

Publisher

Springer Science and Business Media LLC

Subject

Physical and Theoretical Chemistry,Computer Science Applications,Drug Discovery

Link

http://link.springer.com/content/pdf/10.1007/s10822-009-9314-z.pdf

Reference41 articles.

1. Nagamatsu T, Fujita T, Endo K (2000) Perkin 1:33

2. Nagamatsu T, Ukai M, Yoneda F, Brown DJ (1985) Chem Pharm Bull 33:3113

3. Nagamatsu T, Yamasaki H (1995) J Chem Soc Chem Commun 19:2041

4. Nagamatsu T, Yamasaki H, Akiyama T, Hara S, Mori K, Kusakabe H (1999) Synthesis 4:655

5. Nagamatsu T, Fujita T (1999) Chem Commun (Cambridge) 16:1461

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis, characterization and biological applications of a new nano-sized binuclear copper(II) complex containing bathophenanthroline and ellagic acid as ligands;Journal of Molecular Structure;2024-08

2. Triazole derivatives as potential xanthine oxidase inhibitors: Design, enzyme inhibition potential, and docking studies;Archiv der Pharmazie;2024-01-09

3. Past, present and future of xanthine oxidase inhibitors: design strategies, structural and pharmacological insights, patents and clinical trials;RSC Medicinal Chemistry;2023

4. Synthetic heterocyclic derivatives as promising xanthine oxidase inhibitors: An overview;Chemical Biology & Drug Design;2022-07-12

5. Xanthine oxidase inhibitors: patent landscape and clinical development (2015–2020);Expert Opinion on Therapeutic Patents;2020-09-14